MG
OREX

Meditor Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Meditor Group’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-210,000
Closed -$12.9M – 35
2013
Q3 		$12.9M Buy
210,000
+20,000
+11% +$1.35M 1.82% 21
2013
Q2 		$11.1M Buy
+190,000
New +$11.7M 1.5% 20

Other funds holding OREX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Meditor Group's OREX Position: Q4 2013 in Review

Meditor Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2013, closing a stake of 210,000 shares — an estimated $12.9M sold.

Meditor Group first reported a position in OREX in Q2 2013 and held it in 2 quarters. The position peaked at $12.9M in Q3 2013. 124 funds tracked by Wall St. Rank hold OREX as of Q4 2013.

  • Meditor Group reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • Meditor Group sold 210,000 Orexigen Therapeutics, Inc. shares in Q4 2013, an estimated $12.9M.
  • Meditor Group first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 2 quarters.
  • Meditor Group's Orexigen Therapeutics, Inc. position peaked at $12.9M in Q3 2013.
  • 124 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2013.

Based on Meditor Group's 13F filing for Q4 2013, filed 21 Jan 2014.